Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO) (HT348076)

Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)
Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)
Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)
Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)
Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)
Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHT348076
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
Isotipo(VHH-VHH-hFc)-dimer
ID de clonTAS266
Actividad biológica TAS266 is up to 1000-fold more potent than cross-linked DR5 antibody or TRAIL at inducing cell death in cancer cell lines via DR5 activation, with faster downstream caspase activation kinetics [1]. TAS266 potently induces death in human tumor cell lines, with potency ≥1000-fold greater than cross-linked DR5 antibody LBY135 or TRAIL [2]. TAS266 (200 mg/kg; twice weekly) shows no target organ toxicity including hepatotoxicity in cynomolgus monkeys after administration, with its biological activity remaining intact [2]. TAS266 (single dose; weekly) induces tumor regression in a variety of tumor xenograft models, and its antitumor activity with weekly administration is superior to that of DR5 agonist antibodies in pancreatic cancer and colon cancer xenograft models [2]. . Maintained bioactivity despite presence of preexisting or treatment-emergent TAS266-binding IgG antibodies in some animals. . Exhibited superior anti-tumor activity compared with a DR5 agonist antibody in patient-derived pancreatic and colon xenograft models.
Aplicaciones probadas WB
Objetivo CD262, DR5, Death receptor 5, KILLER, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TRAIL receptor 2, TRAIL-R2, TRAILR2, TRICK2, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9
Nivel de endotoxinas < 10 EU/mg
Pureza >95% as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso O14763
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosTAS266
Fondo

Tumor necrosis factor receptor superfamily member 10B (CD262/TRAIL-R2) is a ~47 kDa protein. Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.

1. Hymowitz, SG. et al. (1999) Molecular cell 4, 563-71. PMID: 10549288
Referencias 1. Huet H, et al. TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches[J]. Cancer Research, 2012, 72(8_Supplement): 3853-3853. [HT348076]
2. Papadopoulos KP, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887-895. [HT348076]
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307)
Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107)
Imágenes
  • Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)

    Bioactivity

    Detects Human CD262/TNFRSF10B/TRAIL-R2/DR5 in indirect ELISAs.

  • Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (TAS266)

  • Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)

    Western blot

    Western blot analysis was performed using anti-CD262/TNFRSF10B/DR5 monoclonal antibody at 1μg/ml on various samples.
    Lane 1: recombinant human CD262/TNFRSF10B/DR5 (Catalog No: HT348021), 50ng
    Lane 2: recombinant human CD262/TNFRSF10B/DR5 (Catalog No: HT348021), 30ng

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores